Please login to the form below
MSD appoints new UK head
Mike Nally moves from Swedish division
Merck Sharp and Dohme (MSD) has announced that Mike Nally is to take on the role of managing director of the company's operations in the UK and Ireland.
Nally will take over the role on January 1, 2014, moving from his current position as managing director of MSD in Sweden.
He replaces Deepak Khanna who has been appointed to a new senior VP role at MSD where he will lead the company's oncology efforts across Europe.
As previously announced, Khanna will also step down from his role as president of the Association of the British Pharmaceutical Industry (ABPI) to be replaced by Pfizer's Jonathan Emms.
Commenting on Nally's work in Sweden, MSD said that “he has led the company to become a more customer centric organisation in a dynamic, payer-based environment”.
Featured jobs
- Senior Account Director or Business Unit Director, Healthcare Ad...
-
C£60, 000 – £70, 000 benefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Multi-Channel Account Managers - Road / Home-office based – Full...
-
Competitive salary
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Medical Writer, Healthcare Advertising
-
£35 - £45, 000 benefits
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
-
Scientific Engagement Director
-
Salary will be dependant on experience
- Senior Strategic Planner, Healthcare Brand Communications, Londo...
-
Competitive Salary
- Account Director, Training & Medical Communications, London
-
Competitive Salary
- Medical Writer - Medical Communications
-
£30, 000 - £40, 000 according to skills and experience plus benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Science Writer – Healthcare Advertising
-
Salary TBC
-
Account Manager
-
£40, 000 - £45, 000 benefits
Subscribe to our email news alerts
- Roche starts new late-stage trials of Alzheimer’s candidate
- AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib
- Moving annual total (MAT)
- Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat
- Key success factor (KSF)
- More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease
- How can pharma build bridges with HCPs online?
- NICE set to reject Kyowa Kirin’s Crysvita for XLH
- More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease
- UK firm Nightstar bags FDA fast-track status for gene therapy
- British Business Bank sets up £2.5bn fund for ‘unicorn’ firms
- Commentary: Roseanne’s racist tweet and Sanofi’s swift and surprising riposte
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- Australian Flu and the dilemma of naming diseases
- ...
- Wearables and Healthcare
- What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
- What does a future-proof rep look like?
- Businesses can no longer afford to push ahead with the traditional Key Account Management model....
Quick links
Infographics
